AstraZeneca reports 2025 results and expands stock listing
Pharmaceutical company AstraZeneca announced its 2025 financial results, citing strong commercial performance and multiple blockbuster drugs. The company also began trading on the New York Stock Exchange.
Pharmaceutical giant AstraZeneca released its full-year and fourth-quarter 2025 financial results on February 10, 2026. The company reported a strong commercial performance throughout 2025, with several medicines exceeding $1 billion in annual sales, achieving "blockbuster" status.
CEO Pascal Soriot noted that 16 positive Phase 3 study results were announced during the year. AstraZeneca is also investing heavily in future research, anticipating outcomes from over 20 Phase 3 trial readouts in 2026. The company has more than 100 ongoing Phase 3 studies, incorporating advanced technologies to potentially revolutionize patient outcomes.
In conjunction with the results announcement, AstraZeneca also revealed that its ordinary shares commenced trading on the New York Stock Exchange (NYSE) on February 2, 2026. This move harmonizes the company's listing structure across exchanges in London, New York, and Stockholm, enabling broader shareholder participation in the company's growth.
Further details regarding the 2025 results are available on the company's website via downloadable PDF documents, including the results announcement, presentation, and a clinical trials appendix.